Mounting evidence indicates that dysregulated host type I IFN production can manifest as being a critical driver of pathological blood coagulation during infection but also in such conditions as SLE and SAVI, and possibly during IFN therapy. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.